Archive for the ‘Diabetes’ Category
November 12, 2011
This paper was published online in the New England Journal of Medicine paper in order to coincide with the oral presentation at the 2011 American Society of Nephrology meeting. This report describes renal follow-up of Type 1 diabetic patients enrolled in the DCCT (Diabetes Control and Complications Trial) and EDIC (Epidemiology of Diabetes Interventions and Complications) [...]
June 24, 2011
Free full text available for several days only. This industry-sponsored phase 2 RCT examined the impact of bardoxolone methyl, an oral antioxidant inflammation modulator, on renal function in patients with CKD and diabetes. At 24 and 52 weeks, the intervention arms had improved eGFR compared to placebo. Hard clinical endpoints were not examined in this study.
April 24, 2011
de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, White NH, Danis RP, Davis MD, Hainsworth D, Hubbard LD, Nathan DM. Arch Intern Med. 2011 Mar 14;171(5):412-20
This study is a long-term follow-up of patients with microalbuminuria enrolled in the DCCT/EDIC trial. After a median follow-up of 13 years, intensive glycemic control, lower blood pressure, and improved lipid profile were associated with improved clinical outcomes.
May 1, 2010
House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD. JAMA. 2010 Apr 28;303(16):1603-9
This RCT examined compared a strategy of homocysteine reduction using folic acid, vitamin B6, and vitamin B12 versus placebo in patient with diabetic nephropathy. The active therapy arm experienced a greater decrease in GFR and an increase in vascular events.
May 1, 2010
NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM. N Engl J Med. 2010 Apr 22;362(16):1477-90
9306 patients with IGTT and established cardiovascular disease or cardiovascular risk factors were randomized to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. After a median 5 year follow-up, there was a relative reduction of 14% in the incidence of diabetes in the valsartan group. [...]
March 23, 2010
NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM. N Engl J Med. 2010 Apr 22;362(16):1477-90
This RCT randomized patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo in addition to lifestyle modification. No reduction in cardiovascular events was noted at 5 years, but the incidence of diabetes was reduced; 33.1% in the valsartan group vs 36.8% [...]
March 23, 2010
ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. N Engl J Med. 2010 Apr 29;362(17):1575-85
In the ACCORD BP study, patients with type 2 diabetes at high risk for cardiovascular events were randomized to a target systolic blood pressure of <120 mmHg vs <140 mmHg. After 4.7 years, there was no significant difference in cardiovascular events or mortality but there was an increase in serious adverse events related to anti-hypertensive [...]
March 1, 2009
Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P, VA NEPHRON-D Investigators. Clin J Am Soc Nephrol. 2009 Feb;4(2):361-8
March 1, 2009
Wenzel RR, Littke T, Kuranoff S, Jürgens C, Bruck H, Ritz E, Philipp T, Mitchell A, SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators. J Am Soc Nephrol. 2009 Mar;20(3):655-64
September 1, 2008
McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. Am J Kidney Dis. 2008 Sep;52(3):454-63
May 1, 2008
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. N Engl J Med. 2008 Feb 7;358(6):580-91
February 1, 2008
Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Lancet. 2008 Jan 12;371(9607):117-25
January 1, 2008
Schernthaner G. Nephrol Dial Transplant. 2009 Feb;24(2):396-9
Recent Comments